logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation

< Back

Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation

Drugs

January 2021


Phelinun is in development as a conditioning treatment prior to allogenic haematopoietic stem cell transplantation (HSCT) for various haematological diseases in children and adults. HSCT involves infusing stem cells from a donor into a patient whose bone marrow is damaged or defective. Conditioning treatment prior to HSCT is required in order to kill cancer cells, remove existing bone marrow from the patient and suppress the immune system, to reduce the risk of rejection from the transplant. Conditioning treatment is essential for a successful transplant but there are major associated side effects, including increased mortality. Therefore, there is a need for less toxic conditioning treatments.
Phelinun contains the active ingredient melphalan, which is already used to treat various cancers. It is also intended for the additional use of conditioning prior to HSCT. Phelinun is given by intravenous (IV) infusion and works by interfering in cellular processes, resulting in cell death. If licensed, phelinun will offer an additional treatment option for various cancers and conditioning prior to HSCT.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Get Alerts